Integrative Systems Biology and Experimental Validation Unveil GALNT14 as a Novel Diagnostic Biomarker and Therapeutic Target for Sepsis
Human Mutation · 2026-01 · 2026 (1)
DOI: 10.1155/humu/1474506 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Mutation, online erschienen am 13.05.2026. Verfasst von Xiuqi Zhu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Care Medicine, Jinhua Hospital Affiliated to Zhejiang University, Jinhua, China. Hauptthemen laut MEDLINE: Sepsis, Biomarkers, N-Acetylgalactosaminyltransferases, Systems Biology. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Sepsis
Abstract (Originalsprache)
Background
Sepsis lacks reliable biomarkers for early diagnosis and treatment. This study integrates systems biology approaches, weighted gene coexpression network analysis (WGCNA), and experimental validation to identify novel diagnostic and therapeutic targets.
Methods
Four sepsis‐related GEO datasets were analyzed to identify differentially expressed genes (DEGs) and coexpression modules. Machine learning algorithms screened candidate biomarkers from the intersection of DEGs and module hub genes, validated via ROC analysis and immune infiltration assessment. The biological function of the top candidate was verified in vitro using LPS‐stimulated THP‐1 cells.
Results
GALNT14 was identified as a robust diagnostic biomarker (AUC = 0.79), showing significant correlation with neutrophil and monocyte infiltration. In vitro validation confirmed GALNT14 upregulation in the sepsis model. Functionally, GALNT14 knockdown significantly inhibited proinflammatory cytokines (IL‐1 β , IL‐6, and TNF‐ α ), whereas its overexpression exacerbated the inflammatory response and modulated cell apoptosis.
Conclusion
Through a synergistic framework of AI‐driven bioinformatics and wet‐lab verification, this study identifies GALNT14 as a promising diagnostic biomarker and therapeutic target, mechanistically linking it to the regulation of inflammatory responses in sepsis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Critical Care Medicine, Jinhua Hospital Affiliated to Zhejiang University, Jinhua, China.
- National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, nju.edu.cn.
- Department of Emergency, The Affiliated Huai'an Hospital of Xuzhou Medical University and The Second People's Hospital of Huai'an, Huai'an, China, xzmc.edu.cn.
Zitieren
APA
Zhu, X., Zhai, Y., Yao, J., Chen, Y., & Ge, W. (2026). Integrative Systems Biology and Experimental Validation Unveil GALNT14 as a Novel Diagnostic Biomarker and Therapeutic Target for Sepsis. Human Mutation, 2026(1). https://doi.org/10.1155/humu/1474506
Vancouver
Zhu X, Zhai Y, Yao J, Chen Y, Ge W. Integrative Systems Biology and Experimental Validation Unveil GALNT14 as a Novel Diagnostic Biomarker and Therapeutic Target for Sepsis. Human Mutation. 2026;2026(1). doi:10.1155/humu/1474506
BibTeX
@article{Zhu2026,
author = {Zhu, Xiuqi and Zhai, Yi and Yao, Jiali and Chen, Yue and Ge, Wenhan},
title = {Integrative Systems Biology and Experimental Validation Unveil GALNT14 as a Novel Diagnostic Biomarker and Therapeutic Target for Sepsis},
journal = {Human Mutation},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/humu/1474506}
}
EUVIMED